Phaseline

Companies › Samsung Bioepis

Samsung Bioepis: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Other, Ophthalmology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pembrolizumab (SB27)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Stage IINov 2026
Aflibercept (SB15)
Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor
VEGFA, PGFPhase 2Neovascular Age-related Macular Degeneration–
SB35
IL-17A receptor antagonist
IL17RAPhase 1HealthyJun 2027
E303
nectin-4 targeting antibody-drug conjugate
NECTIN4Phase 1Advanced Solid TumorsJul 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07844343Aflibercept (SB15)Phase 2Neovascular Age-related Macular DegenerationOphthalmologySep 2026
NCT06268613Pembrolizumab (SB27)Phase 1Non-small Cell Lung Cancer Stage IIOncologyNov 2026
NCT07789964SB35Phase 1HealthyOtherJun 2027
NCT06348199Pembrolizumab (SB27)Phase 3Non-small Cell Lung Cancer Stage IVOncologyAug 2027
NCT07524348E303Phase 1Advanced Solid TumorsOncologyJul 2030

From the company's SEC filings

Complete response letters from FDA

Targets

PDCD1 (1) NECTIN4 (1) IL17RA (1) VEGFA (1) PGF (1)

Companies with the same targets

Akeso Regeneron Pharmaceuticals Roche Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Sichuan Baili Pharmaceutical Mabwell (Shanghai) Bioscience Jiangsu Simcere Pharmaceutical Shenyang Sunshine Pharmaceutical

Companies built like this

CStone Pharmaceuticals Shanghai Fudan-Zhangjiang Bio-Pharmaceutical TaiRx Alvotech Swiss RemeGen

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.